A Phase 1/2 interventional study of CR-001 and Paclitaxel in Locally Advanced / Metastatic Solid Tumors, sponsored by Crescent Biopharma, Inc.. Recruiting at 36 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Crescent Biopharma, Inc. · Phase 1/2, Interventional, and Treatment
Drug: Paclitaxel · Drug: trifluridine and tipiracil · Drug: Pemetrexed · Drug: Carboplatin · Drug: Oxaliplatin · Drug: Gemcitabin · Drug: Cisplatin · Drug: Capecitabine · Drug: FOLFOX
CR-001 Dose Expansion 3A: First-line (1L) Non-small cell lung cancer · CR-001 Dose Expansion 3B: First-line (1L) colorectal cancer · CR-001 Dose Expansion 3C: Third-line (3L) colorectal cancer · CR-001 Dose Expansion 3D: First-line (1L) endometrial carcinoma · CR-001 Dose Expansion 3E: First-line (1L) gastric/gastroesophageal cancer · CR-001 Dose Expansion 3F: Second-line (2L) gastric/gastroesophageal cancer · CR-001 Dose Expansion 3G: First-line (1L) Biliary tract cancer
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,057 studies in Neoplasm Metastasis with a site in United States — 345 open to participants now, 544 under way, 58 of them phase 3. Neoplasm Metastasis · United States.
Among the 2,057 studies in Neoplasm Metastasis with a site in United States, this one is the 106th largest by planned enrollment of the 1,866 interventional ones that give a count, is one of 86 that started in 2026, is one of 268 in phase 1/2, reaches primary completion later than 455 of the 542 other live ones, and was the 1,992nd registered.
4,052 studies on the registry are indexed under Neoplasm Metastasis; 893 are open to participants now.
Browse Neoplasm Metastasis studies →345 of the 2,057 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 18+
SystImmune Inc. · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 693 Neoplasm Metastasis studies recruiting now, 541 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,057 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 978 · Phase 2 855 · Phase 3 186 · Phase 4 15
First in 1978; this study’s year is marked. 86 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 540 is above the median of 50 across 3,275 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 43 across the 1,866 interventional studies, 100 across the 139 observational. Of the 1,391 that completed or were terminated, 602 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
927 of 2,057 have an industry lead sponsor. The 10 most frequent:
Crescent Biopharma, Inc. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Crescent Biopharma, Inc. has 2 studies filed under Neoplasm Metastasis — fewer than ten, so there is no comparison to draw.
203 of the studies in Neoplasm Metastasis with a site in United States that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03525873Phase 3M.D. Anderson Cancer CenterA Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy | 2026-12-31 |
| NCT03927885Phase 3M.D. Anderson Cancer CenterOpen Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer | 2026-12-31 |
| NCT06947928Phase 3TuHURA Biosciences, Inc.Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma | 2027-03-31 |
| NCT06506955Phase 3Taiho Oncology, Inc.Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. | 2027-04 |
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
Add all 203 to your calendar (.ics) → With an account.
Among the 2,057 studies in Neoplasm Metastasis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) (RP2D) in participants with locally advanced or metastatic solid tumors.
The study will be 4 parts: dose escalation, backfill, dose expansion and dose optimization cohorts. The study will follow a stepwise approach, beginning with a typical dose escalation in participants with selected indications of advanced solid tumors. Additional participants will enroll in the backfill part at select dose levels that have been previously cleared for safety by the safety review committee. Dose expansion will enroll 7 cohorts of participants who will receive CR-001 in combination with chemotherapy. In dose optimization, participants will be randomized to one of two CR-001 dose levels.
All participants will undergo a screening period, a treatment period of up to 2 years, a safety follow-up period, and long-term efficacy and survival follow-up. During the treatment period, participants will undergo clinical and safety assessments including disease assessment scans and blood laboratory safety, pharmacokinetic, and pharmacodynamic assessments. After treatment ends, disease scans will continue until disease progression, and long-term follow-up visits will be conducted by telephone every 3 months.
The criteria were revised on the registry on Oct 20, 2026. See what changed
Key Inclusion Criteria
For dose escalation or backfill: progressing from, intolerant to, or ineligible for (due to unavailability or ) local standard of care therapies and have one of the following locally advanced or tumor types:
For dose expansion: have one of the following locally advanced or metastatic tumor types:
Key Exclusion Criteria for all parts
Key Exclusion Criteria for dose expansion only
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Escalating dose levels of CR-001 to define the maximum tolerated dose of CR-001 in participants with locally advanced or metastatic solid tumors who are refractory to or unable to tolerate standard of care treatment, or for whom standard of care treatment is unavailable
Drug: CR-001
Escalating dose levels of CR-001 Indication-specific cohort populations will be tested
Drug: CR-001
CR-001 in combination with paclitaxel or pemetrexed + carboplatin
Drug: CR-001 · Drug: Paclitaxel · Drug: Pemetrexed · Drug: Carboplatin
CR-001 in combination with FOLFOX
Drug: CR-001 · Drug: FOLFOX
CR-001 in combination with trifluridine + tipiracil
Drug: CR-001 · Drug: trifluridine and tipiracil
CR-001 in combination with paclitaxel + carboplatin
Drug: CR-001 · Drug: Paclitaxel · Drug: Carboplatin
CR-001 in combination capecitabine + oxaliplatin
Drug: CR-001 · Drug: Oxaliplatin · Drug: Capecitabine
CR-001 in combination with paclitaxel
Drug: CR-001 · Drug: Paclitaxel
CR-001 in combination with gemcitabine + cisplatin
Drug: CR-001 · Drug: Gemcitabin · Drug: Cisplatin
monotherapy dose level (DL)-X Indication-specific cohort populations will be tested
Drug: CR-001
monotherapy dose level (DL)-Y Indication-specific cohort populations will be tested
Drug: CR-001
Intravenous Infusion
Intravenous Infusion
Oral
Intravenous Infusion
Intravenous Infusion
Intravenous Infusion
Intravenous Infusion
Intravenous Infusion
Oral
Intravenous Infusion + Oral
Part 1 (Dose Escalation) - Incidence and nature of dose-limiting toxicities
Per cohort
Time frame: From the first dose of study drug up until approximately 1 month
Part 1 (Dose Escalation) - Characterization of the maximum tolerated dose, if applicable
Per Cohort
Time frame: From the first dose of study drug up until approximately 1 month
All parts - Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and treatment - emergent serious adverse events
Events graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)
Time frame: From the first dose of study drug until 90 days after the last dose of study drug
All parts - Incidence and severity of TEAEs leading to dose modifications
Time frame: From the first dose of study drug until 90 days after the last dose of study drug
All parts - Incidence and severity of TEAEs leading to treatment discontinuation
Time frame: From the first dose of study drug until 90 days after the last dose of study drug
Part 3 (Dose Expansion) - Overall response rate (ORR) by Investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
Time frame: From the first dose of study drug until 90 days after the last dose of study drug
All parts - Determination of recommended Phase 2 dose(s)
Time frame: From the first dose of study drug until 90 days after the last dose of study drug
All parts - Serum CR-001 pharmacokinetic parameters
AUC0--inf after a single dose and steady state parameters, as appropriate
Time frame: Predose until up to approximately 36 months
All parts - Serum CR-001 pharmacokinetic parameters
AUClast after a single dose and steady state parameters, as appropriate
Time frame: Predose until up to approximately 36 months
All parts - Serum CR-001 pharmacokinetic parameters
Cmax after a single dose and steady state parameters, as appropriate
Time frame: Predose until up to approximately 36 months
All parts - Serum CR-001 pharmacokinetic parameters
Tmax after a single dose and steady state parameters, as appropriate
Time frame: Predose until up to approximately 36 months
All parts - Serum CR-001 pharmacokinetic parameters
Vd after a single dose and steady state parameters, as appropriate
Time frame: Predose until up to approximately 36 months
All parts - Serum CR-001 pharmacokinetic parameters
CL after a single dose and steady state parameters, as appropriate
Time frame: Predose until up to approximately 36 months
All parts - Serum CR-001 pharmacokinetic parameters
t½ after a single dose and steady state parameters, as appropriate
Time frame: Predose until up to approximately 36 months
All parts - Incidence of participants with detectable antidrug antibodies
Time frame: Predose until up to approximately 36 months
Parts 1, 2 and 4 - Overall response rate
Time frame: From the first dose of study drug until up to approximately 36 months
Parts 1, 2 and 4 - Duration of response
Time frame: From the first dose of study drug until up to approximately 36 months
Parts 1, 2 and 4 - Time to response
Time frame: From the first dose of study drug until up to approximately 36 months
Parts 1, 2 and 4 - Progression free survival
Time frame: From the first dose of study drug until up to approximately 36 months
Parts 1, 2 and 4 - Overall survival
Time frame: From the first dose of study drug until up to approximately 36 months
Parts 1, 2 and 4 - Best percent change in target lesions
Time frame: From the first dose of study drug until up to approximately 36 months
Part 3 (Dose Expansion) - DOR, DCR, TTR, PFS, OS, and best percentage change in target lesions
Time frame: From the first dose of study drug until up to approximately 36 months
Not enrolling at this site — choose another above.
Started Feb 2026 (actual). Primary completion is estimated for Feb 2029, 36 months after the start.
Of 129 industry-sponsored phase 1/2 interventional studies under Neoplasm Metastasis, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 89. This study's planned 36 months is below that.
Counting every sponsor, half of 215 studies reached it within 62 months; a quarter within 41 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
Drug: Paclitaxel · Drug: trifluridine and tipiracil · Drug: Pemetrexed · Drug: Carboplatin · Drug: Oxaliplatin · Drug: Gemcitabin · Drug: Cisplatin · Drug: Capecitabine · Drug: FOLFOX
CR-001 Dose Expansion 3A: First-line (1L) Non-small cell lung cancer · CR-001 Dose Expansion 3B: First-line (1L) colorectal cancer · CR-001 Dose Expansion 3C: Third-line (3L) colorectal cancer · CR-001 Dose Expansion 3D: First-line (1L) endometrial carcinoma · CR-001 Dose Expansion 3E: First-line (1L) gastric/gastroesophageal cancer · CR-001 Dose Expansion 3F: Second-line (2L) gastric/gastroesophageal cancer · CR-001 Dose Expansion 3G: First-line (1L) Biliary tract cancer
Drug: Paclitaxel · Drug: trifluridine and tipiracil · Drug: Pemetrexed · Drug: Carboplatin · Drug: Oxaliplatin · Drug: Gemcitabin · Drug: Cisplatin · Drug: Capecitabine · Drug: FOLFOX
CR-001 Dose Expansion 3A: First-line (1L) Non-small cell lung cancer · CR-001 Dose Expansion 3B: First-line (1L) colorectal cancer · CR-001 Dose Expansion 3C: Third-line (3L) colorectal cancer · CR-001 Dose Expansion 3D: First-line (1L) endometrial carcinoma · CR-001 Dose Expansion 3E: First-line (1L) gastric/gastroesophageal cancer · CR-001 Dose Expansion 3F: Second-line (2L) gastric/gastroesophageal cancer · CR-001 Dose Expansion 3G: First-line (1L) Biliary tract cancer
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001
Crescent Biopharma, Inc.